Reductions in ETP after the addition of the different anticoagulant drugs.

<p>Reduction in ETP after the addition of (A) dabigatran, (B) heparin, (C) LMWH, (D) Fondaparinux, and (E) rivaroxaban in plasma from patients with Child A, B, and C cirrhosis and healthy controls. Bars indicate medians with the error bars representing interquartile ranges. ** = P<0.01 compared to controls.</p

Correlation between AT/FX levels and reductions in thrombin generation after fondaparinux.

<p>Correlation between the percentual reduction in ETP when tested in the presence of TM after addition of 0.5 µg/ml fondaparinux and <b>(A)</b> plasmatic AT levels and <b>(B)</b> plasmatic FX levels in plasma from patients with cirrhosis.</p

Correlation between FX levels and reductions in thrombin generation after rivaroxaban.

<p>Correlation between plasmatic FX levels and the percentual reduction in peak thrombin generation when tested in the presence of TM after addition of rivaroxaban at 25 ng/ml in plasma from patients with cirrhosis.</p

Demographic and clinical characteristics of the study population.

<p>HCV: Hepatitis C virus, NASH: Non-alcoholic steatohepatitis, PBC: Primary biliary cirrhosis, PSC: Primary sclerosing cholangitis, DM: Diabetes Mellitus.</p><p>Data are expressed as number (%), mean [SD], or median [range].</p

Coagulation parameters in cirrhotic patients and controls.

<p>INR: International normalized ratio, AT: Antithrombin.</p><p>Data are expressed as median [range].</p

Correlation between FII levels and reductions in thrombin generation after dabigatran.

<p>Correlation between plasmatic FII levels and percentual reduction of peak thrombin values when tested in the presence of TM after addition of 300/ml dabigatran in plasma from patients with cirrhosis.</p

Inhibition of in vitro thrombin generation after addition of various anticoagulant drugs to plasma taken from patients with cirrhosis or plasma from healthy controls.

<p>TM: thrombomodulin, ETP: Endogenous thrombin potential, Velindex: velocity index, LMWH: low molecular weight heparin.</p><p>Shown are the percentual inhibition of the ETP, peak, or velocity index, and the percentual increase in the lag time. Data are expressed as median percentages with interquartile range.</p>*<p> = P<0.05, ** = P<0.01 compared to controls.</p

Development of clinically significant infection over time in relation to the recipient <i>NOD2</i> R702W genotype.

<p>Occurrence of clinically significant infection in days after OLT in relation to the recipient <i>NOD2</i> R702W genotype. CC = wildtype, TT homozygote for mutation, CT = heterozygote. The numbers below the Kaplan – Meier curves represent the number of individuals ‘at risk’ per genotype at particular time points after transplantation.</p